Expression levels of FBXW7 and MDM2&nbsp;E3 ubiquitin ligases and their c‑Myc and p53 substrates in patients with dysplastic nevi or melanoma

Mozuraitiene,Julija; Gudleviciene,Zivile; Vincerzevskiene,Ieva; Laurinaviciene,Aida; Pamedys,Justinas

doi:10.3892/ol.2020.12298

Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their c‑Myc and p53 substrates in patients with dysplastic nevi or melanoma

Authors:
- Julija Mozuraitiene
- Zivile Gudleviciene
- Ieva Vincerzevskiene
- Aida Laurinaviciene
- Justinas Pamedys
View Affiliations

Affiliations: Outpatient Clinic, National Cancer Institute, LT‑08660 Vilnius, Lithuania, Biobank, LT‑08660 Vilnius, Lithuania, Laboratory of Clinical Oncology, National Cancer Institute, LT‑08660 Vilnius, Lithuania, Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Vilnius University, LT‑03101 Vilnius, Lithuania, National Center of Pathology Affiliated to Vilnius University Hospital SantarosKlinikos, LT‑08406 Vilnius, Lithuania
Published online on: November 12, 2020 https://doi.org/10.3892/ol.2020.12298
Article Number: 37
Copyright: © Mozuraitiene et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

E3 ubiquitin ligases are of interest as drug targets due to their involvement in the regulation of the functions and interactions of several proteins. Various E3 ligase complexes are considered oncogenes or tumor suppressors associated with the development of melanoma. These proteins regulate the functions of various signaling pathways and proteins, such as p53 and Notch. The aim of the present study was to determine the expression levels of F‑box and WD repeat domain‑containing 7 (FBXW7), c‑Myc, MDM2 and p53 proteins in samples from patients with dysplastic nevi or melanoma, and to evaluate their association with clinicopathological parameters and prognosis of the disease. Paraffin blocks with postoperative material from 100 patients diagnosed with dysplastic moles or melanoma were used in the present study. Tissue microarrays and immunohistochemistry were used to examine FBXW7, c‑Myc, MDM2 and p53 protein expression. The results revealed that there was significantly lower FBXW7 expression in advanced melanoma compared with dysplastic nevus, melanoma in situ and stage pT1 melanoma (P<0.001). Additionally, there was a statistically significant association between the expression levels of FBXW7 and the morphological type of the tumor (P<0.001). In addition, there was a strong positive association between FBXW7 expression and the changes in c‑Myc expression (P<0.02), and a strong trend was observed between decreased FBXW7 expression and a higher risk of death in patients, with the major factor in patient mortality being the stages of melanoma. Additionally, p53 expression was associated with the depth of melanoma invasion and the morphological type of the tumor. In summary, FBXW7 expression exhibited the highest statistically significant prognostic value and associations with advanced melanoma. As the majority of FBXW7 substrates are oncoproteins, their degradation by FBXW7 may highlight these proteins as potential targets for the treatment of melanoma.

View Figures

View References

1	Morrow JK, Lin HK, Sun SC and Zhang S: Targeting ubiquitination for cancer therapies. Future Med Chem. 7:2333–2350. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ma J, Guo W and Li C: Ubiquitination in melanoma pathogenesis and treatment. Cancer Med. 6:1362–1377. 2017. View Article : Google Scholar : PubMed/NCBI
3	Aydin IT, Melamed RD, Adams SJ, Castillo-Martin M, Demir A, Bryk D, Brunner G, Cordon-Cardo C, Osman I, Rabadan R, et al: FBXW7 mutations in melanoma and a new therapeutic paradigm. J Natl Cancer Inst. 106:dju1072014. View Article : Google Scholar : PubMed/NCBI
4	Xie CM, Wei W and Sun Y: Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J Genet Genomics. 40:97–106. 2013. View Article : Google Scholar : PubMed/NCBI
5	Welcker M and Clurman BE: FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 8:83–93. 2008. View Article : Google Scholar : PubMed/NCBI
6	Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 586:1409–1418. 2012. View Article : Google Scholar : PubMed/NCBI
7	Huang HL, Weng HY, Wang LQ, Yu CH, Huang QJ, Zhao PP, Wen JZ, Zhou H and Qu LH: Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther. 11:1155–1165. 2012. View Article : Google Scholar : PubMed/NCBI
8	Liu H, Wang K, Fu H and Song J: Low expression of the ubiquitin ligase FBXW7 correlates with poor prognosis of patients with colorectal cancer. Int J Clin Exp Pathol. 11:413–419. 2018.PubMed/NCBI
9	Cheng Y, Chen G, Martinka M, Ho V and Li G: Prognostic significance of Fbw7 in human melanoma and its role in cell migration. J Invest Dermatol. 133:1794–1802. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wang L, Ye X, Liu Y, Wei W and Wang Z: Aberrant regulation of FBW7 in cancer. Oncotarget. 5:2000–2015. 2014. View Article : Google Scholar : PubMed/NCBI
11	Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A: Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 432:775–779. 2004. View Article : Google Scholar : PubMed/NCBI
12	Pei D, Zhang Y and Zheng J: Regulation of p53: A collaboration between Mdm2 and Mdmx. Oncotarget. 3:228–235. 2012. View Article : Google Scholar : PubMed/NCBI
13	Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P and Mahdi AA: Regulation of glucose metabolism by p53: Emerging new roles for the tumor suppressor. Oncotarget. 2:948–957. 2011. View Article : Google Scholar : PubMed/NCBI
14	Muller PAJ and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wade M, Li Y and Wahl G: MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96. 2013. View Article : Google Scholar : PubMed/NCBI
16	Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P and Eeles RA: Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 63:6643–6650. 2003.PubMed/NCBI
17	Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB and Varley JM: Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 20:4621–4628. 2001. View Article : Google Scholar : PubMed/NCBI
18	Felsher DW and Bishop JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 4:199–207. 1999. View Article : Google Scholar : PubMed/NCBI
19	Marinkovic D, Marinkovic T, Mahr B, Hess J and Wirth T: Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer. 110:336–342. 2004. View Article : Google Scholar : PubMed/NCBI
20	Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM and Felsher DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:102–104. 2002. View Article : Google Scholar : PubMed/NCBI
21	Gabay M, Li Y and Felsher DW: MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 4:1–14. 2014. View Article : Google Scholar
22	Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 431:1112–1117. 2004. View Article : Google Scholar : PubMed/NCBI
23	Sato M, Rodriguez-Barrueco R, Yu J, Do C, Silva JM and Gautier J: MYC is a critical target of FBXW7. Oncotarget. 6:3292–3305. 2015. View Article : Google Scholar : PubMed/NCBI
24	Meyer N and Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ross DA and Wilson GD: Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br J Surg. 85:46–51. 1998. View Article : Google Scholar : PubMed/NCBI
26	Greulich KM, Utikal J, Peter RU and Krähn G: c-MYC and nodular malignant melanoma. A case report. Cancer. 89:97–103. 2000. View Article : Google Scholar : PubMed/NCBI
27	Kraehn GM, Utikal J, Udart M, Greulich KM, Bezold G, Kaskel P, Leiter U and Peter RU: Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer. 84:72–79. 2001. View Article : Google Scholar : PubMed/NCBI
28	Kanzler MH and Mraz-Gernhard S: Primary cutaneous malignant melanoma and its precursor lesions: Diagnostic and therapeutic overview. J Am Acad Dermatol. 45:260–276. 2001. View Article : Google Scholar : PubMed/NCBI
29	Lin X, Sun R, Zhao X, Zhu D, Zhao X, Gu Q, Dong X, Zhang D, Zhang Y, Li Y, et al: C-myc overexpression drives melanoma metastasis by promoting vasculogenic mimicry via c-myc/snail/Bax signaling. J Mol Med (Berl). 95:53–67. 2017. View Article : Google Scholar : PubMed/NCBI
30	Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W and Zhang R: Targeting MDM2-p53 interaction for cancer therapy: Are we there yet? Curr Med Chem. 21:553–574. 2014. View Article : Google Scholar : PubMed/NCBI
31	Freedman DA, Wu L and Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 55:96–107. 1999. View Article : Google Scholar : PubMed/NCBI
32	Momand J, Wu HH and Dasgupta G: MDM2 - master regulator of the p53 tumor suppressor protein. Gene. 242:15–29. 2000. View Article : Google Scholar : PubMed/NCBI
33	Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW and Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:857–860. 1993. View Article : Google Scholar : PubMed/NCBI
34	Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
35	Li Q and Lozano G: Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 19:34–41. 2013. View Article : Google Scholar : PubMed/NCBI
36	Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol Med. 13:23–31. 2007. View Article : Google Scholar : PubMed/NCBI
37	Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual, 8th edition. Springer; 2017
38	Cheng Y and Li G: Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 31:75–87. 2012. View Article : Google Scholar : PubMed/NCBI
39	Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, OConnor O, Hoffmann A, Elenitoba-Johnson KS and Pagano M: Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol. 14:375–385. 2012. View Article : Google Scholar : PubMed/NCBI
40	Min SH, Lau AW, Lee TH, Inuzuka H, Wei S, Huang P, Shaik S, Lee DY, Finn G, Balastik M, et al: Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell. 46:771–783. 2012. View Article : Google Scholar : PubMed/NCBI
41	Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004. View Article : Google Scholar : PubMed/NCBI
42	Davis RJ, Welcker M and Clurman BE: Tumor suppression by the Fbw7 ubiquitin ligase: Mechanisms and opportunities. Cancer Cell. 26:455–464. 2014. View Article : Google Scholar : PubMed/NCBI
43	Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG and Colombo E: Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ. J Cell Biol. 182:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
44	Grim JE, Gustafson MP, Hirata RK, Hagar AC, Swanger J, Welcker M, Hwang HC, Ericsson J, Russell DW and Clurman BE: Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol. 181:913–920. 2008. View Article : Google Scholar : PubMed/NCBI
45	Welcker M, Orian A, Grim JE, Eisenman RN and Clurman BE: A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol. 14:1852–1857. 2004. View Article : Google Scholar : PubMed/NCBI
46	Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 101:9085–9090. 2004. View Article : Google Scholar : PubMed/NCBI
47	Reavie L, Buckley SM, Loizou E, Takeishi S, Aranda-Orgilles B, Ndiaye-Lobry D, et al: Regulation of c-Myc ubiquitination controls CML initiation and progression. Cancer Cell. 23:362–375. 2013. View Article : Google Scholar : PubMed/NCBI
48	Niezgoda A, Niezgoda P and Czajkowski R: Novel approaches to treatment of advanced melanoma: A review on targeted therapy and immunotherapy. Biomed Res Int. 2015:851382015. View Article : Google Scholar
49	Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB and Penn LZ: MYC deregulation in primary human cancers. Genes (Basel). 8:2–30. 2017. View Article : Google Scholar
50	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
51	Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et al: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 6:67442015. View Article : Google Scholar : PubMed/NCBI
52	Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
53	Houben R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S, Müller CS, Schrama D, Wischhusen J and Becker JC: High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One. 6:e220962011. View Article : Google Scholar : PubMed/NCBI
54	Winder M and Virós A: Mechanisms of drug resistance in melanoma. Handb Exp Pharmacol. 249:91–108. 2018. View Article : Google Scholar : PubMed/NCBI
55	Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, et al: Paradoxical role for wild-type p53 in driving therapy resistance in melanoma. Mol Cell. 77:633–644.e5. 2020. View Article : Google Scholar : PubMed/NCBI
56	Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, et al: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 409:207–211. 2001. View Article : Google Scholar : PubMed/NCBI
57	Karst AM, Dai DL, Martinka M and Li G: PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene. 24:1111–1116. 2005. View Article : Google Scholar : PubMed/NCBI
58	Onel K and Cordon-Cardo C: MDM2 and prognosis. Mol Cancer Res. 2:1–8. 2004.PubMed/NCBI
59	Sun Y: E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia. 8:645–654. 2006. View Article : Google Scholar : PubMed/NCBI
60	Polsky D, Bastian B, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C and Osman I: HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 61:7642–7646. 2001.PubMed/NCBI
61	Rajabi P, Karimian P and Heidarpour M: The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma. J Res Med Sci. 17:452–455. 2012.PubMed/NCBI
62	Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, et al: HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 94:1803–1806. 2002. View Article : Google Scholar : PubMed/NCBI
63	Kimura T, Gotoh M, Nakamura Y and Arakawa H: hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94:431–436. 2003. View Article : Google Scholar : PubMed/NCBI
64	Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L and Bosenberg MW: Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer. 45:447–454. 2006. View Article : Google Scholar : PubMed/NCBI